Antibiotic resistance of Helicobacter pylori in the European part of the Russian Federation: first results
- Authors: Maev I.V.1, Andreev D.N.1, Govorun V.M.2, Ilina E.N.2, Kucheryavyy Y.A.1, Oganesian T.S.3, Melnikova E.V.4, Zayratyants O.V.1, Parfenova T.V.5, Dzhedzheia L.V.5, Kirillova N.V.6, Maevskaya E.A.1, Fomenko A.K.1, Lobanova E.G.1, Zaborovskii A.V.1, Kriukov K.A.7
-
Affiliations:
- Yevdokimov Moscow State University of Medicine and Dentistry
- Federal Research And Clinical Center of Physical-Chemical Medicine Federal Medical Biological Agency
- City Clinical Hospital №4
- Medical Center for Diagnostics and Prevention
- Laboratory «Litekh»
- «Litekh»
- Yaroslavl State Medical University
- Issue: Vol 92, No 8 (2020)
- Pages: 24-28
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/43537
- DOI: https://doi.org/10.26442/00403660.2020.08.000761
- ID: 43537
Cite item
Full Text
Abstract
Aim. Determine the primary antibiotic resistance of Helicobacter pylori (H. pylori) strains isolated from patients living in the European part of the Russian Federation.
Materials and methods. As part of a clinical laboratory study, from 2015 to 2018, 27 gastrobiopsy samples obtained from H. pylori-infected patients were analyzed. H. pylori infection was verified using a rapid urease test or a 13C-urea breath test. The values of the minimum inhibitory concentration (MIC) of antibiotics were determined by the diffusion method using E-test strips (BioMerieux, France) according to the recommendations of the manufacturer. The sensitivity of the isolates was determined for 6 antibacterial drugs (amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline, rifampicin).
Results. According to the data obtained, resistance to amoxicillin was 0%, clarithromycin – 11.1%, metronidazole – 59.3%, levofloxacin – 3.7%, tetracycline – 0%, and rifampicin – 14.8%. Dual resistance to clarithromycin and metronidazole was recorded in two isolates (7.4%).
Conclusion. Thus, the first results of the evaluation of H. pylori antibiotic resistance in the European part of the Russian Federation indicate a low resistance of the microorganism to clarithromycin and quite high to metronidazole.
Full Text
##article.viewOnOriginalSite##About the authors
I. V. Maev
Yevdokimov Moscow State University of Medicine and Dentistry
Email: dna-mit8@mail.ru
ORCID iD: 0000-0001-6114-564X
д.м.н., проф., зав. каф. пропедевтики внутренних болезней и гастроэнтерологии ФГБОУ ВО «МГМСУ им. А.И. Евдокимова», заслуженный врач РФ, заслуженный деятель науки РФ
Russian Federation, MoscowD. N. Andreev
Yevdokimov Moscow State University of Medicine and Dentistry
Author for correspondence.
Email: dna-mit8@mail.ru
ORCID iD: 0000-0002-4007-7112
к.м.н., доц. каф. пропедевтики внутренних болезней и гастроэнтерологии ФГБОУ ВО «МГМСУ им. А.И. Евдокимова»
Russian Federation, MoscowV. M. Govorun
Federal Research And Clinical Center of Physical-Chemical Medicine Federal Medical Biological Agency
Email: dna-mit8@mail.ru
ORCID iD: 0000-0003-0837-8764
акад. РАН, д.б.н., ген. директор ФГБУ «ФНКЦ Физико-химической медицины» ФМБА России
Russian Federation, MoscowE. N. Ilina
Federal Research And Clinical Center of Physical-Chemical Medicine Federal Medical Biological Agency
Email: dna-mit8@mail.ru
ORCID iD: 0000-0003-0130-5079
чл.-кор. РАН, д.б.н., зам. ген. директора по научной работе ФГБУ «ФНКЦ Физико-химической медицины» ФМБА России
Russian Federation, MoscowYu. A. Kucheryavyy
Yevdokimov Moscow State University of Medicine and Dentistry
Email: dna-mit8@mail.ru
ORCID iD: 0000-0001-7760-2091
к.м.н., доц. каф. пропедевтики внутренних болезней и гастроэнтерологии ФГБОУ ВО «МГМСУ им. А.И. Евдокимова»
Russian Federation, MoscowT. S. Oganesian
City Clinical Hospital №4
Email: dna-mit8@mail.ru
ORCID iD: 0000-0003-2980-1007
к.м.н., ГБУЗ ГКБ №4
Russian Federation, MoscowE. V. Melnikova
Medical Center for Diagnostics and Prevention
Email: dna-mit8@mail.ru
ORCID iD: 0000-0003-3352-5949
к.м.н., зам. ген. директора по научной работе ООО «Медицинский центр диагностики и профилактики»
Russian Federation, YaroslavlO. V. Zayratyants
Yevdokimov Moscow State University of Medicine and Dentistry
Email: dna-mit8@mail.ru
ORCID iD: 0000-0003-3606-3823
д.м.н., проф., зав. каф. патологической анатомии ФГБОУ ВО «МГМСУ им. А.И. Евдокимова»
Russian Federation, MoscowT. V. Parfenova
Laboratory «Litekh»
Email: dna-mit8@mail.ru
ORCID iD: 0000-0001-6631-1993
с.н.с., ООО «Лаборатория Литех»
Russian Federation, MoscowL. V. Dzhedzheia
Laboratory «Litekh»
Email: dna-mit8@mail.ru
ORCID iD: 0000-0003-2299-4483
зав. КДЛ OOO «Лаборатория Литех»
Russian Federation, MoscowN. V. Kirillova
«Litekh»
Email: dna-mit8@mail.ru
ORCID iD: 0000-0003-3281-1695
с.н.с., ООО НПФ «Литех»
Russian Federation, MoscowE. A. Maevskaya
Yevdokimov Moscow State University of Medicine and Dentistry
Email: dna-mit8@mail.ru
ORCID iD: 0000-0002-3323-3279
к.м.н., ассистент каф. пропедевтики внутренних болезней и гастроэнтерологии ФГБОУ ВО «МГМСУ им. А.И. Евдокимова»
Russian Federation, MoscowA. K. Fomenko
Yevdokimov Moscow State University of Medicine and Dentistry
Email: dna-mit8@mail.ru
ORCID iD: 0000-0002-1794-7263
клинический ординатор каф. пропедевтики внутренних болезней и гастроэнтерологии ФГБОУ ВО «МГМСУ им. А.И. Евдокимова»
Russian Federation, MoscowE. G. Lobanova
Yevdokimov Moscow State University of Medicine and Dentistry
Email: dna-mit8@mail.ru
д.м.н., проф. каф. фармакологии ФГБОУ ВО «МГМСУ им. А.И. Евдокимова»
Russian Federation, MoscowA. V. Zaborovskii
Yevdokimov Moscow State University of Medicine and Dentistry
Email: dna-mit8@mail.ru
ORCID iD: 0000-0002-7923-9916
д.м.н., зав. каф. фармакологии ФГБОУ ВО «МГМСУ им. А.И. Евдокимова»
Russian Federation, MoscowK. A. Kriukov
Yaroslavl State Medical University
Email: dna-mit8@mail.ru
ORCID iD: 0000-0002-5598-6132
студент 4-го курса ФГБОУ ВО ЯГМУ
Russian Federation, YaroslavlReferences
- Маев И.В., Самсонов А.А., Андреев Д.Н. и др. Клиническое значение инфекции Helicobacter pylori. Клин мед. 2013;91(8):4-12 [Maev IV, Samsonov AA, Andreev DN, et al. Clinical significance of Helicobacter pylori infection. Klin. Med. 2013;91(8):4-12 (In Russ.)].
- Suzuki H, Warren R, Marshall B. Helicobacter Pylori; Springer: Tokyo, Japan, 2016.
- Ивашкин В.Т., Маев И.В., Лапина Т.Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(1):55-70 [Ivashkin VT, Mayev IV, Lapina TL, et al. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(1):55-70. (In Russ.)]. doi: 10.22416/1382-4376-2018-28-1-55-70
- Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus. Report. Gut. 2017;66(1):6-30. doi: 10.1136/gutjnl-2016-312288
- Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112(2):212-39. doi: 10.1038/ajg.2016.563
- Sugano K, Tack J, Kuipers EJ, et al.; faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353-67. doi: 10.1136/gutjnl-2015-309252
- Lee YC, Chen TH, Chiu HM, et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut. 2013;62:676-82. doi: 10.1136/gutjnl-2012-302240
- Malfertheiner P, Link A, Selgrad M. Helicobacter pylori: perspectives and time trends. Nat Rev Gastroenterol Hepatol. 2014;11(10):628-38. doi: 10.1038/nrgastro.2014.99
- Iwańczak F, Iwańczak B. Treatment of Helicobacter pylori infection in the aspect of increasing antibiotic resistance. Adv Clin Exp Med. 2012;21(5):671-80.
- Vianna JS, Ramis IB, Ramos DF, et al. Drug resistance in Helicobacter pylori. Arq Gastroenterol. 2016;53(4):215-23. doi: 10.1590/S0004-28032016000400002
- Маев И.В., Андреев Д.Н. Молекулярно-генетические предикторы резистентности к антихеликобактерной терапии. Терапевтический архив. 2017;89(8):5-12 [Maev IV, Andreev DN. Molecular genetic predictors of resistance to anti-Helicobacter pylori therapy. Therapeutic Archive. 2017;89(8):5-12 (In Russ.)]. doi: 10.17116/ terarkh20178985-12
- Savoldi A, Carrara E, Graham DY, et al. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology. 2018;155(5):1372-82.e17. doi: 10.1053/j.gastro.2018.07.007
- Маев И.В., Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Эрадикационная терапия инфекции Helicobacter pylori: обзор мировых тенденций. Терапевтический архив. 2014;86(3):94-9 [Maev IV, Kucheryavyi Yu.A, Andreev DN, Barkalova EV. Eradication therapy for Helicobacter pylori infection: review of world trends. Therapeutic Archive. 2014;86(3):94-9 (In Russ.).]
- Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2014;12:177-86. doi: 10.1016/j.cgh.2013.05.028
- Perez Aldana L, Kato M, Nakagawa S, et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter. 2002;7:306-9.
- Megraud F, Coenen S, Versporten A, et al.; Study Group participants. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62(1):34-42. doi: 10.1136/gutjnl-2012-302254
- Boyanova L, Ilieva J, Gergova G, et al. Numerous risk factors for Helicobacter pylori antibiotic resistance revealed by extended anamnesis: a Bulgarian study. J Med Microbiol. 2012;61(Pt 1):85-93. doi: 10.1099/jmm.0.035568-0
- Lim SG, Park RW, Shin SJ, et al. The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use. Dig Liver Dis. 2016;48(4):385-90. doi: 10.1016/j.dld.2015.12.001
- Андреев Д.Н., Маев И.В., Кучерявый Ю.А. и др. Эффективность и безопасность антихеликобактерной терапии у пациентов с сопутствующим хроническим гепатитом С. Терапевтический архив. 2016;4:75-81 [Andreev DN, Maev IV, Kucheryavyi YA, et al. The efficiency and safety of anti-Helicobacter pylori therapy in patients with concomitant chronic hepatitis C. Therapeutic Archive. 2016;88(4):75-81 (In Russ.)]. doi: 10.17116/terarkh201688475-81
- McNulty CA, Lasseter G, Shaw I, et al. Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered? Aliment Pharmacol Ther. 2012;35(10):1221-30. doi: 10.1111/j.1365-2036.2012.05083.x
- Бордин Д.С., Эмбутниекс Ю.В., Вологжанина Л.Г. и др. Европейский регистр Helicobacter pylori (Hp-Eureg): анализ данных 2360 больных, получавших терапию первой линии в России. Терапевтический архив. 2018;90(2):35-42 [Bordin DS, Embutnieks YV, Vologzhanina LG, et al. European Registry on the management of Helicobacter pylori infection (Hp-EuReg): analysis of 2360 patients receiving first-line therapy in Russia. Therapeutic Archive. 2018;90(2):35-42 (In Russ.).] doi: 10.26442/terarkh201890235-42
- Самсонов А.А., Гречушников В.Б., Андреев Д.Н. и др. Оценка фармакоэкономических показателей лечения пациентов с заболеваниями, ассоциированными с Helicobacter pylori. Терапевтический архив. 2014; 86(8):57-61 [Samsonov AA, Grechushnikov VB, Andreev DN, et al. Pharmacoeconomic evaluation of treatment in patients with Helicobacter pylori-associated diseases. Therapeutic Archive. 2014;86(8):56-61 (In Russ.).]
- Андреев Д.Н., Дичева Д.Т., Маев И.В. Возможности оптимизации эрадикационной терапии инфекции Helicobacter pylori в современной клинической практике. Терапевтический архив. 2017;89(2):84-90 [Andreev DN, Dicheva DT, Maev IV. Possibilities for optimization of eradication therapy for Helicobacter pylori infection in modern clinical practice. Therapeutic Archive. 2017;89(2):84-90 (In Russ.).]. doi: 10.17116/terarkh201789284-90
- Ko SW, Kim YJ, Chung WC, Lee SJ. Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: Systemic review and meta-analysis. Helicobacter. 2019;24(2):e12565. doi: 10.1111/hel.12565
- Andreev DN, Maev IV, Dicheva DT. Efficiency of the Inclusion of Rebamipide in the Eradication Therapy for Helicobacter pylori Infection: Meta-Analysis of Randomized Controlled Studies. J Clin Med. 2019;8(9). pii: E1498. doi: 10.3390/jcm8091498
Supplementary files
![](/img/style/loading.gif)